Power On: SkyWater’s Quantum Leap and Nakamoto’s Bitcoin PivotGlobal Report·Jul 17 at 04:11 AMSKYT-0.33%NAKA-2.01%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jul 9 at 12:05 PMVRAX0.00%IONS+1.22%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jul 8 at 04:05 PMAPVO+0.46%BRTX-7.17%
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·Jul 8 at 12:05 PMCUPR+0.76%TVRD-1.95%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Jul 7 at 12:05 PMCRNX+0.10%AKTX-6.45%
Tvardi Therapeutics shares are trading higher after Phase 1 results for TTI‑109 showed rapid conversion, dose‑proportional PK above STAT3 IC₅₀, and up to 60% reductions in STAT3‑driven immune cells.benzinga_article·Jul 7 at 09:57 AMTVRD-1.95%
Tvardi Therapeutics: TTI-109 showed rapid conversion, favorable safety, and immune modulation, supporting phase II plansQuartr·Jul 7 at 09:36 AMTVRD-1.95%
Tvardi Therapeutics: TTI-101 reduced fibrosis and inflammation in IPF, but discontinuations were higher with nintedanibQuartr·Jul 7 at 06:33 AMTVRD-1.95%
Tvardi Therapeutics reports Phase 1 data for STAT3 inhibitor prodrug TTI-109 showing improved tolerabilityPUBT·Jul 7 at 06:01 AMTVRD-1.95%
Top Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor?rttnews·Jun 29 at 10:02 PMUPC-10.55%TVRD-1.95%
